As of June 15, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

Here's the latest list of major overbought players in this sector.

Cardinal Health, Inc (NYSE:CAH)

  • On April 30, Cardinal Health reported mixed third-quarter financial results. “An excellent third quarter extends our FY26 momentum, due to the durability and resilience of our business,” said Jason Hollar, CEO of Cardinal Health. “We were pleased to see strong operating performance led by Pharmaceutical and Specialty Solutions and our three growth businesses, positioning us for long-term value creation and giving us the confidence to again raise our fiscal 2026 outlook.” The company's stock gained around 15% over the past month and has a 52-week high of $233.60.
  • RSI Value: 77.7                                
  • CAH Price Action: Shares of Cardinal Health fell 1.2% to close at $223.85 on Friday.
  • Edge Stock Ratings: 68.46 Momentum score with Value at 34.96.

TG Therapeutics Inc (NASDAQ:TGTX)

  • On June 9, TG Therapeutics announced positive topline Phase 1 data for its subcutaneous BRIUMVI (ublituximab-xiiy) for myasthenia gravis (MG), a chronic autoimmune neuromuscular disorder that causes weakness and rapid fatigue in voluntary muscles. The company's stock gained around 23% over the past five days and has a 52-week high of $50.41.
  • RSI Value: 79.8
  • TGTX Price Action: Shares of TG Therapeutics gained 3.1% to close at $49.52 on Friday.

Amneal Pharmaceuticals Inc (NASDAQ:AMRX)

  • On June 5, Amneal Pharmaceuticals announced new interim results from Phase 4 study reinforcing reported benefits of Parkinson’s treatment Crexont. The company's stock gained around 36% over the past month and has a 52-week high of $16.61
  • RSI Value: 76.9
  • AMRX Price Action: Shares of Amneal Pharmaceuticals fell 0.9% to close at $16.20 on Friday.

Don't miss out on the full BZ Edge Rankings—compare all the key stocks now.

Photo via Shutterstock